A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
A3AR 激动剂可预防化疗引起的疼痛性周围神经病变
基本信息
- 批准号:8634753
- 负责人:
- 金额:$ 29.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-04-01 至 2018-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenosine A3 ReceptorAdverse effectsAfferent NeuronsAgonistAnti-Inflammatory AgentsAnti-inflammatoryAntibodiesAttenuatedBasic ScienceBortezomibChronicClinicClinicalClinical ResearchClinical TrialsComplexDataDevelopmentDiseaseDoseDose-LimitingEquilibriumFoundationsGeneticGlutamate TransporterGlutamate-Ammonia LigaseGlutamatesHomeostasisHyperalgesiaIL6 geneInflammatoryInterdisciplinary StudyInterleukin-1Interleukin-10InvestigationKnock-outLeadLifeLinkMAP Kinase GeneMAPK Signaling Pathway PathwayMAPK11 geneMAPK14 geneMAPK3 geneMediatingMedicalMitochondriaModificationNerve FibersNeuronsNeuropathyOutcomePaclitaxelPainPatientsPeripheralPeripheral Nervous System DiseasesPeroxonitritePlatinumProcessProductionProteasome InhibitorProteinsPublic HealthPurinergic P1 ReceptorsQuality of lifeResearch ProposalsSensorySignal TransductionSiteSpinalSpinal CordStressSynapsesTNF geneTaxane CompoundTestingTherapeuticTimeToxic effectTranslationsVinca AlkaloidsVincristineallodyniaanalogattenuationbasebench to bedsidecentral sensitizationchemotherapychronic neuropathic paincytokinedrug efficacymitochondrial dysfunctionneoplasticneuroinflammationneurotransmissionnew therapeutic targetnitrationnovel strategiesnovel therapeuticsoxaliplatinpainful neuropathypreventpublic health relevancetaxanetherapeutic target
项目摘要
DESCRIPTION (provided by applicant): Chemotherapy-induced peripheral neuropathy (CIPN) accompanied by chronic neuropathic pain is the major dose-limiting toxicity of widely used antitumoral agents in the taxane (e.g., paclitaxel), platinum-complex (e.g., oxaliplatin), vinca alkaloids (e.g., vincristine) & proteasome-inhibitor (e.g., bortezomib) classes.1-3 Thus, CIPN is one of most common causes of dose reduction & discontinuation of what is otherwise a life-saving therapy.2-7 Addressing this major public health issue by identifying therapeutic targets with immediate potential translation to the clinic is of paramount significance. We have identified
A3 adenosine receptor (A3AR) agonism as a new viable therapeutic strategy for treating or reversing CIPN (Appendix 1 & ref8). Noteworthy, the selective A3AR agonists IB-MECA & its 2-chloro analogue (Cl-IBMECA) are in advanced clinical trials as antiinflammatory & antitumor agents.9,10 This proposal highlights a multidisciplinary research plan that builds upon our preliminary data to explore the breadth of A3AR agonist applicability in CIPN while investigating underlying protective mechanism(s) of action. Using IB-MECA, three Specific Aims will test our central hypothesis: A3AR agonists are effective therapeutics in CIPN caused by chemotherapeutics with distinct antitumor mechanisms of action (paclitaxel, oxaliplatin & bortezomib) with beneficial effects exerted at the level of the peripheral sensory afferent (PSA) neuron &/or spinal cord. In Aim 1, we will test if 1) IB-MECA blocks & reverses neuropathic pain, 2) the effects of IB-MECA are specific to an A3AR mediated mechanism using pharmacological & genetic knockout approaches, 3) potential central & peripheral site(s) of action underlie IB-MECA's action & 4) IB-MECA prevents chemotherapy-evoked degeneration of intraepidermal nerve fibers & primary afferent spontaneous discharge. In Aim 2, we will investigate the mechanism(s) whereby IB-MECA attenuates neuropathic pain through mitoprotective effects in PSA. Finally, in Aim 3, we will investigate if IB-MECA's effects include attenuating neuroinflammation &/or the dysregulation of glutamate homeostasis in the spinal cord, processes known to be essential to central sensitization. We will focus on NF¿B & MAPK (ERK1/2, p38) signaling & glial-derived pro (TNF¿, IL1¿, & IL6)/anti (IL10)-inflammatory cytokines, as well as, the effects on the expression & activities of spinal glutamate transporters (neuronal & glial) & glial glutamine synthetase. If our hypothesis holds true, the outcome of our results are anticipated to provide the pharmacological rationale for "proof-of-concept" for the use
of selective A3AR agonists as a new approach in CIPN. From a translational perspective, this could conceivably lead to a "fast track" investigation of IB-MECA for CIPN. This exciting possibility underscores the immediate clinical impact that our research proposal may have in this critical & unmet medical setting. Given the breadth of disorders impacted by A3AR agonists understanding their mechanism-based effects has far-reaching basic science & clinical implications.
描述(由申请人提供):伴随慢性神经性疼痛的化疗诱导的周围神经病变(CIPN)是紫杉烷类(例如,紫杉醇),铂络合物(例如,奥沙利铂),长春花生物碱(例如,长春新碱)和蛋白酶体抑制剂(例如,硼替佐米)类别。1 -3因此,CIPN是减少剂量和停止本可挽救生命的治疗的最常见原因之一。2 -7通过确定可立即转化为临床的治疗靶点来解决这一重大公共卫生问题至关重要。我们已经确定
A3腺苷受体(A3 AR)激动作为治疗或逆转CIPN的新的可行治疗策略(附录1和参考文献8)。值得注意的是,选择性A3 AR激动剂IB-MECA及其2-氯类似物(Cl-IBMECA)作为抗肿瘤药物正在进行高级临床试验。9,10该提案强调了一项多学科研究计划,该计划以我们的初步数据为基础,探索A3 AR激动剂在CIPN中的适用性范围,同时研究潜在的保护作用机制。使用IB-MECA,三个特定目标将测试我们的中心假设:A3 AR激动剂是治疗由化疗药物引起的CIPN的有效治疗药物,具有不同的抗肿瘤作用机制(紫杉醇、奥沙利铂和硼替佐米),并在外周感觉传入水平发挥有益作用(PSA)神经元和/或脊髓。在目标1中,我们将测试1)IB-MECA是否阻断和逆转神经性疼痛,2)IB-MECA的作用是否对使用药理学和遗传敲除方法的A3 AR介导的机制具有特异性,3)潜在的中枢和外周作用位点是IB-MECA作用的基础,以及4)IB-MECA是否预防化疗诱发的表皮内神经纤维变性和初级传入自发放电。在目标2中,我们将研究IB-MECA通过PSA中的线粒体保护作用减轻神经性疼痛的机制。最后,在目标3中,我们将研究IB-MECA的作用是否包括减弱神经炎症和/或脊髓中谷氨酸稳态的失调,已知这是中枢致敏所必需的过程。我们将专注于NF?B和MAPK(ERK 1/2,p38)信号传导和神经胶质源性促(TNF和IL 6)/抗(IL 10)炎性细胞因子,以及对脊髓谷氨酸转运体(神经元和神经胶质)和神经胶质谷氨酰胺合成酶的表达和活性的影响。如果我们的假设成立,我们的结果预计将提供药理学原理的“概念验证”的使用
选择性A3 AR激动剂作为CIPN的新方法。从翻译的角度来看,这可能会导致CIPN的IB-MECA的“快速通道”调查。这种令人兴奋的可能性强调了我们的研究提案在这种关键和未满足的医疗环境中可能产生的直接临床影响。考虑到A3 AR激动剂影响的疾病的广度,了解其基于机制的作用具有深远的基础科学和临床意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DANIELA SALVEMINI其他文献
DANIELA SALVEMINI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DANIELA SALVEMINI', 18)}}的其他基金
Isolation of GPR160 for biochemical analysis of the activation mechanism and development of a high throughput screening assay to identify small molecule inhibitors
分离 GPR160,用于激活机制的生化分析,并开发高通量筛选方法来鉴定小分子抑制剂
- 批准号:
10176852 - 财政年份:2020
- 资助金额:
$ 29.08万 - 项目类别:
A3AR agonists as a novel approach to mitigate chemotherapy induced neurotoxicity
A3AR 激动剂作为减轻化疗引起的神经毒性的新方法
- 批准号:
10460227 - 财政年份:2019
- 资助金额:
$ 29.08万 - 项目类别:
Role of opioid-induced S1P/S1PR1 axis activation in neuroinflammatory reponses
阿片类药物诱导的 S1P/S1PR1 轴激活在神经炎症反应中的作用
- 批准号:
9751234 - 财政年份:2018
- 资助金额:
$ 29.08万 - 项目类别:
Preserving opioid analgesia using a novel adenosinergic approach
使用新型腺苷能方法保持阿片类镇痛作用
- 批准号:
8974700 - 财政年份:2015
- 资助金额:
$ 29.08万 - 项目类别:
Preserving opioid analgesia using a novel adenosinergic approach
使用新型腺苷能方法保持阿片类镇痛作用
- 批准号:
9095273 - 财政年份:2015
- 资助金额:
$ 29.08万 - 项目类别:
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
A3AR 激动剂可预防化疗引起的疼痛性周围神经病变
- 批准号:
9042993 - 财政年份:2013
- 资助金额:
$ 29.08万 - 项目类别:
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
A3AR 激动剂可预防化疗引起的疼痛性周围神经病变
- 批准号:
8501971 - 财政年份:2013
- 资助金额:
$ 29.08万 - 项目类别:
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
A3AR 激动剂可预防化疗引起的疼痛性周围神经病变
- 批准号:
9278122 - 财政年份:2013
- 资助金额:
$ 29.08万 - 项目类别:
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
A3AR 激动剂可预防化疗引起的疼痛性周围神经病变
- 批准号:
8830342 - 财政年份:2013
- 资助金额:
$ 29.08万 - 项目类别:
Role of ceramide in morphine hyperalgesia and tolerance
神经酰胺在吗啡痛觉过敏和耐受中的作用
- 批准号:
7528339 - 财政年份:2008
- 资助金额:
$ 29.08万 - 项目类别:
相似海外基金
The Biology of Microglia: Adenosine A3 Receptor Suppression
小胶质细胞的生物学:腺苷 A3 受体抑制
- 批准号:
RGPIN-2019-06289 - 财政年份:2022
- 资助金额:
$ 29.08万 - 项目类别:
Discovery Grants Program - Individual
The Biology of Microglia: Adenosine A3 Receptor Suppression
小胶质细胞的生物学:腺苷 A3 受体抑制
- 批准号:
RGPIN-2019-06289 - 财政年份:2021
- 资助金额:
$ 29.08万 - 项目类别:
Discovery Grants Program - Individual
Molecular basis for adenosine A3 receptor agonists in the treatment of migraine
腺苷A3受体激动剂治疗偏头痛的分子基础
- 批准号:
10532300 - 财政年份:2021
- 资助金额:
$ 29.08万 - 项目类别:
Molecular basis for adenosine A3 receptor agonists in the treatment of migraine
腺苷A3受体激动剂治疗偏头痛的分子基础
- 批准号:
10363152 - 财政年份:2021
- 资助金额:
$ 29.08万 - 项目类别:
The Biology of Microglia: Adenosine A3 Receptor Suppression
小胶质细胞的生物学:腺苷 A3 受体抑制
- 批准号:
RGPIN-2019-06289 - 财政年份:2020
- 资助金额:
$ 29.08万 - 项目类别:
Discovery Grants Program - Individual
The Biology of Microglia: Adenosine A3 Receptor Suppression
小胶质细胞的生物学:腺苷 A3 受体抑制
- 批准号:
RGPIN-2019-06289 - 财政年份:2019
- 资助金额:
$ 29.08万 - 项目类别:
Discovery Grants Program - Individual
Use of fluorescence correlation spectroscopy to study the adenosine A3-receptor in microdomains of single living cells
使用荧光相关光谱研究单个活细胞微区中的腺苷 A3 受体
- 批准号:
G0800006/1 - 财政年份:2009
- 资助金额:
$ 29.08万 - 项目类别:
Research Grant
Role of adenosine A3 receptor in suppressing prostate cancer
腺苷A3受体在抑制前列腺癌中的作用
- 批准号:
7516278 - 财政年份:2008
- 资助金额:
$ 29.08万 - 项目类别: